Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genesis Fertility Center PCLBKK:GFC 43 Debt-to-EBITDA is 11.00 as of Jun. 2026, which is 3338% above its 10-year median of 0.32. GuruFocus rates BKK:GFC with a GF Score™ of 43/100 and a GF Value™ of ฿3.54 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 478 Healthcare Providers & Services companies, Genesis Fertility Center PCL ranks better than 79.08% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Genesis Fertility Center PCL's Debt-to-EBITDA or its related term are showing as below:
BKK:GFC'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.19 Med: 0.32 Max: 2.18
Current: 0.61
During the past 5 years, the highest Debt-to-EBITDA Ratio of Genesis Fertility Center PCL was 2.18. The lowest was 0.19. And the median was 0.32.
BKK:GFC's Debt-to-EBITDA is ranked better than 79.08% of 478
companies
in the Healthcare Providers & Services industry
Industry Median: 2.195
vs BKK:GFC: 0.61
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Genesis Fertility Center PCL Debt-to-EBITDA Related Terms
Genesis Fertility Center PCL Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BKK:GFC vs HCA, THC, DVA: Debt-to-EBITDA Comparison
For the Medical Care Facilities subindustry, Genesis Fertility Center PCL's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genesis Fertility Center PCL Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Genesis Fertility Center PCL's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Genesis Fertility Center PCL's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Genesis Fertility Center PCL (BKK:GFC) has a Debt-to-EBITDA of 11.00 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Genesis Fertility Center PCL. This is 3338% above median its historical median of 0.32. Over the past decade, Genesis Fertility Center PCL's Debt-to-EBITDA has ranged from 0.19 to 2.18. According to the industry distribution chart, Genesis Fertility Center PCL ranks #100 out of 478 companies in the Healthcare Providers & Services industry, placing it in the top 20.9%.
Is Genesis Fertility Center PCL's Debt-to-EBITDA too high?
Genesis Fertility Center PCL's current Debt-to-EBITDA of 11.00 is 3338% above median its 10-year median of 0.32. Over the past 10 years, this metric has ranged from a low of 0.19 to a high of 2.18. The Healthcare Providers & Services industry median Debt-to-EBITDA is 2.20. Genesis Fertility Center PCL's value of 11.00 is 401.1% above this industry median. Based on the distribution chart, Genesis Fertility Center PCL ranks #100 out of 478 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Genesis Fertility Center PCL has a GF Score™ of 43/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genesis Fertility Center PCL's Debt-to-EBITDA compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Genesis Fertility Center PCL ranks #100 out of 478 companies for Debt-to-EBITDA. This places Genesis Fertility Center PCL in the top 21% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 2.20. Genesis Fertility Center PCL's value of 11.00 is 401.1% above this benchmark. Historically, Genesis Fertility Center PCL's own Debt-to-EBITDA has ranged from 0.19 to 2.18 over the past decade. While the company's 10-year median is 0.32 vs. the industry median of 2.20, Genesis Fertility Center PCL has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.20, based on 478 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genesis Fertility Center PCL's current Debt-to-EBITDA of 11.00 is 401.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Genesis Fertility Center PCL. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genesis Fertility Center PCL's current Debt-to-EBITDA is 11.00, which is 3338% above median its own 10-year median of 0.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genesis Fertility Center PCL stock overvalued right now?
Based on GuruFocus' analysis, Genesis Fertility Center PCL (BKK:GFC) is currently considered Significantly Undervalued. The stock's GF Value™ is ฿3.54, compared to a current price of ฿2.14 — trading 39.5% below its estimated fair value. The current Debt-to-EBITDA is 11.00, which is 3338% above median its 10-year median of 0.32 and 401.1% above the Healthcare Providers & Services industry median of 2.20. Genesis Fertility Center PCL's overall GF Score™ is 43/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Genesis Fertility Center PCL (BKK:GFC), the current Debt-to-EBITDA is 11.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genesis Fertility Center PCL (BKK:GFC) Overvalued in 2026?
Based on GuruFocus' analysis, Genesis Fertility Center PCL stock appears to be undervalued.
The current stock price of ฿2.14 is trading 39.5% below its estimated GF Value™ of ฿3.54.
GuruFocus considers Genesis Fertility Center PCL to be Significantly Undervalued.
Key valuation signals for BKK:GFC:
Debt-to-EBITDA: 11.00 (3338% above median its 10-year median of 0.32)
GF Value™: ฿3.54 vs. price of ฿2.14 (39.5% below fair value)
Industry Position: 401.1% above the Healthcare Providers & Services median (#100 of 478)
No single metric tells the full story. See the BKK:GFC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genesis Fertility Center PCL is engaged in providing treatment and counseling services to infertile people, chromosome analysis by NGS technique services and providing investment services in other businesses consulting and management services. It operates in single segment of providing treatment and counseling services to infertile people.
43GF Score
Get the complete analysis for BKK:GFC
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:GFC has been successfully added to your 
